Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611579 | 1.00 | ALDH1A1 (0.70) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL4006089 | 0.92 | DRD2 (0.61) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL4148809 | 0.92 | DRD2 (0.61) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL4007370 | 0.92 | DRD2 (0.61) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL4006081 | 0.92 | DRD2 (0.61) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL612333 | 0.90 | ALDH1A1 (0.58) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL612332 | 0.90 | ALDH1A1 (0.58) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL612581 | 0.89 | ALDH1A1 (0.59) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL612772 | 0.88 | ALDH1A1 (0.57) | ALDH1A1DRD2DRD3USP30SMN1; SMN2 | |
| SCHEMBL612274 | 0.85 | TSHR (0.60) | ALDH1A1DRD2DRD3SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | claimed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 57/4885DRD2 1035/4885DRD3 1141/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | ALDH1A1 76/4885DRD2 1544/4885DRD3 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.